PROSTest is a novel 30-gene mRNA liquid biopsy that enables accurate risk stratification for prostate cancer, guiding biopsy decisions and detecting MRD. PROSTest demonstrated 92.3% accuracy, 93.1% sensitivity, 91.4% specificity, 93.7% PPV, 90.8% NPV, and a failure rate of <0.1%. It outperforms PSA and mpMRI, and shows greater sensitivity than PSMA PET in detecting MRD. NETest is a clinically validated 55-gene transcriptomic assay for neuroendocrine tumors, with diagnostic accuracy exceeding 90%. It stratifies disease activity, supports patient surveillance, and predicts response to radioligand therapy (RLT) with PPV >95% and NPV >90%. It also correlates with progression-free and overall survival. Together, PROSTest and NETest deliver biologically driven decision support through reproducible, rapid-turnaround blood tests, advancing personalized care and enabling more efficient clinical trial design.
